Skip to main content
. 2022 Jul 26;140(10):1104–1118. doi: 10.1182/blood.2022015956

Figure 6.

Figure 6

TFIs improve AMG 562-mediated control of ALL in vivo. (A) Timeline of in vivo experiment: PDX-ALL cells were transplanted into NSG mice. T cells (4 donors) were stimulated in vitro for 14 days continuously or with TFI cells (days 7-14) and subsequently injected into NSG mice 28 days post engraftment. Mice were treated with AMG 562/control BiTE = 5 ng/mL on days 1 and 8 post T-cell injection. T-cell function and ALL burden was analyzed via bioluminescence imaging and flow cytometry. (B) Quantification of bioluminescence imaging signals (left panel) and images of mice on day 42 after engraftment (right panel). See supplemental Figure 7B for images of all timepoints. (C) Flow cytometry analysis of PDX-ALL cells detected in PB on day 35 and in BM on day 43. Representative plots from 1 T-cell donor are shown. (D) CD3+ T-cell expansion in PB on day 35. Representative plots from 1 T-cell donor are shown. (E) Human cytokine levels detected in murine plasma on day 30. All graphs present mean ± SEM values. BM, bone marrow; cBiTE, control BiTE, bispecific control construct; CONT, continuously; PB, peripheral blood; PDX-ALL, patient-derived xenograft acute lymphoblastic leukemia; NSG, NOD.Cg-Prkdcscid IL2rgtm1Wjl/SzJ; ±SEM, standard error of the mean; TFI(s), treatment-free interval(s).